Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201420 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
A Phase 2 study, sponsored by Navidea Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02201420 is a Phase 2 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT02201420, a Phase 2 study, has completed, sponsored by Navidea Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.
Interventions
- DRUG Tc 99m tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201420
The ClinicalTrials.gov registry entry for NCT02201420 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navidea Biopharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc 99m tilmanocept is the first listed.
NCT02201420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02201420 about?
NCT02201420 is a clinical study titled "Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT". The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.
What is the current status of trial NCT02201420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2014-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02201420?
The interventions under investigation include: Tc 99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT02201420?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.